Marshall Wace
BCRX icon

Marshall Wace’s BioCryst Pharmaceuticals BCRX Stock Holding History

Marshall Wace’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.35M Buy
+246,477
New +$1.91M ﹤0.01% 1696
2025
Q4 		– Sell
-731,411
Closed -$5.55M – 2961
2025
Q3 		$5.55M Buy
731,411
+588,099
+410% +$4.9M 0.01% 1146
2025
Q2 		$1.28M Buy
+143,312
New +$1.33M ﹤0.01% 1757
2024
Q4 		– Sell
-33,257
Closed -$253K – 2583
2024
Q3 		$253K Buy
+33,257
New +$253K ﹤0.01% 2213
2023
Q4 		– Sell
-134,362
Closed -$951K – 2183
2023
Q3 		$951K Buy
+134,362
New +$965K ﹤0.01% 1517
2023
Q2 		– Sell
-126,699
Closed -$1.06M – 2473
2023
Q1 		$1.06M Buy
+126,699
New +$1.22M ﹤0.01% 1782
2022
Q3 		– Sell
-35,574
Closed -$376K – 3341
2022
Q2 		$376K Sell
35,574
-1,050,272
-97% -$10.8M ﹤0.01% 2929
2022
Q1 		$17.7M Buy
+1,085,846
New +$17.4M 0.03% 549
2021
Q2 		– Sell
-182,905
Closed -$1.86M – 2653
2021
Q1 		$1.86M Buy
+182,905
New +$1.89M 0.01% 1364
2020
Q3 		– Sell
-50,277
Closed -$239K – 1574
2020
Q2 		$239K Sell
50,277
-21,383
-30% -$85.4K ﹤0.01% 1374
2020
Q1 		$143K Buy
+71,660
New +$197K ﹤0.01% 1255
2014
Q3 		– Sell
-218,413
Closed -$2.79M – 879
2014
Q2 		$2.79M Buy
+218,413
New +$2.12M 0.04% 344

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Marshall Wace's BCRX Position: Q1 2026 in Review

Marshall Wace opened a new position in BioCryst Pharmaceuticals (BCRX) in Q1 2026: 246,477 shares worth $2.35M. The stake represents ﹤0.01% of the portfolio and ranks #1696 among its holdings. This is a return to the name: Marshall Wace previously reported a position in BCRX as recently as Q3 2025.

Marshall Wace first reported a position in BCRX in Q2 2014 and has held it in 12 quarters since. The position peaked at $17.7M in Q1 2022. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Marshall Wace held 246,477 shares of BioCryst Pharmaceuticals worth $2.35M as of Q1 2026.
  • BioCryst Pharmaceuticals was a new Marshall Wace position in Q1 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #1696 holding.
  • Marshall Wace first reported a position in BioCryst Pharmaceuticals in Q2 2014 and has held it in 12 quarters since.
  • Marshall Wace's BioCryst Pharmaceuticals position peaked at $17.7M in Q1 2022.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.